Notícias Medexus Pharmaceuticals Inc - MDP | Ações Toronto Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
Canadá
TSX
Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc (MDP) Notícias

Medexus Pharmaceuticals Inc (MDP)

4,39

0,09

( 2,09% )

Atualizado: 11:41:32

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update

Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors

Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Medexus Schedules First Quarter 2023 Conference Call

Treosulfan NDA Resubmitted to FDA

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

Treosulfan Pivotal Study Results Published

Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference

Medexus to Participate in the 34th Annual Roth Conference

Medexus Pharmaceuticals Announces Deal for Gleolan in the United States

Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures

Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Medexus Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições